Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study designed to assess the pharmacokinetics and safety
of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to
those in subjects with normal hepatic function.
Twenty-four subjects will be selected and enrolled according to the subject selection
criteria: 6 subjects with mild stable chronic hepatic impairment (Group I), 6 subjects with
moderate stable chronic hepatic impairment (Group II), 6 subjects with severe stable chronic
hepatic impairment (Group III) and 6 subjects with normal hepatic function (Group IV).